New York headquartered Immune Pharmaceuticals Inc.'s stock recorded a trading volume of 1.84 million shares, and finished Friday's trading session 9.09% higher at $0.25. Shares of the Company, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, are trading below their 50-day moving average by 23.34%. The stock has a Relative Strength Index (RSI) of 40.08.
On September 16th, 2016, Immune Pharmaceuticals announced that its Board of Directors has approved to designate Maxim Pharmaceuticals Inc., one of the Company's existing subsidiaries, as the dedicated entity to develop and commercialize, and hold the intellectual property related to AmiKet® and other related pain and neurology assets. In addition, the Company has entered into a binding agreement with NPT, a syndicate of experienced healthcare investors, pursuant to which NPT or its designees have agreed to purchase up to $20 million of the Maxim's capital stock with an initial funding of $5 million to occur within thirty days. Pursuant to the Binding Agreement, immediately following the $5 million initial funding by NPT, Immune will expand Maxim's Board of Directors to five members which will include one NPT representative and Maxim's newly hired Chief Executive Officer. See our free and comprehensive research report on IMNP at:
Last Friday, Paris, France headquartered Sanofi's shares recorded a trading volume of 2.77 million shares, which was above their three months average volume of 2.23 million shares. The stock ended the session 0.05% higher at $37.75. The Company's shares are trading 3.27% below their 50-day moving average. Moreover, shares of Sanofi, which researches, develops, manufactures, and markets various therapeutic solutions, have an RSI of 38.15.
On September 23rd, 2016, research firm Piper Jaffray initiated a 'Neutral' rating on the Company's stock.
On September 26th, 2016, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for dupilumab for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease. The application has been given a Prescription Drug User Fee Act (PDUFA) target action date of March 29th, 2017. SNY free research report PDF is just a click away at:
Dublin, Ireland headquartered Shire PLC's stock ended the day 1.75% lower at $187.70 with a total trading volume of 861,585 shares. Shares of the Company, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, are trading 3.27% above their 200-day moving average. The stock has an RSI of 38.98.
On September 26th, 2016, research firm HSBC Securities downgraded the Company's stock rating from 'Buy' to 'Hold'.
On October 05th, 2016, Shire announced that the US Patent & Trademark Office's Patent Trial and Appeal Board has issued their decision upholding the validity of US Patent No. 6,773,720 related to Shire's LIALDA® (mesalamine) product. The petition seeking to institute inter-parties review was filed with the US Patent and Trademark Office's Patent Trial and Appeal Board in April of 2015 by the Coalition for Affordable Drugs II L.L.C. Fund. Shire stated that LIALDA remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of UC. Sign up for your complimentary report on SHPG at:
Shares in Houston, Texas headquartered Nobilis Health Corp. recorded a trading volume of 172,123 shares, and ended Friday's session flat at $3.48. The stock has gained 2.65% in the last month, 45.61% over the previous three months, and 23.40% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.36% and 17.03%, respectively. Furthermore, shares of Nobilis Health, which together with its subsidiaries, acquires and manages ambulatory surgical centers and healthcare facilities in the US, have an RSI of 55.81.
On September 19th, 2016, Nobilis Health announced that it has acquired an Ambulatory Surgery Center (ASC) in Dickinson, TX which will operate as a Hospital Outpatient Department of Nobilis' Bellaire Surgical Hospital. This ASC expands Nobilis' geographic reach into the southeast Houston Metro area, allowing it to reach doctors and patients currently unserved by its existing Houston-area facilities. Register for free on Stock-Callers.com and download the latest research report on HLTH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA